Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

ACS chemical neuroscience molecule spotlight on Suvorexant.

Hopkins CR.

ACS Chem Neurosci. 2012 Sep 19;3(9):647-8. Review.

2.

Suvorexant: something new for sleep?

Reddy A, Puvvada SC, Kommisetti S, El-Mallakh RS, Lippmann S.

Acta Neuropsychiatr. 2015 Feb;27(1):53-5. doi: 10.1017/neu.2014.31. Epub 2014 Nov 14.

PMID:
25397996
3.

Suvorexant: a dual orexin receptor antagonist for the treatment of sleep onset and sleep maintenance insomnia.

Patel KV, Aspesi AV, Evoy KE.

Ann Pharmacother. 2015 Apr;49(4):477-83. doi: 10.1177/1060028015570467. Epub 2015 Feb 9. Review.

PMID:
25667197
4.

Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant.

Herring WJ, Snyder E, Budd K, Hutzelmann J, Snavely D, Liu K, Lines C, Roth T, Michelson D.

Neurology. 2012 Dec 4;79(23):2265-74. doi: 10.1212/WNL.0b013e31827688ee. Epub 2012 Nov 28.

PMID:
23197752
5.

Suvorexant for the treatment of insomnia.

Jacobson LH, Callander GE, Hoyer D.

Expert Rev Clin Pharmacol. 2014 Nov;7(6):711-30. doi: 10.1586/17512433.2014.966813. Review.

PMID:
25318834
6.

Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial.

Michelson D, Snyder E, Paradis E, Chengan-Liu M, Snavely DB, Hutzelmann J, Walsh JK, Krystal AD, Benca RM, Cohn M, Lines C, Roth T, Herring WJ.

Lancet Neurol. 2014 May;13(5):461-71. doi: 10.1016/S1474-4422(14)70053-5. Epub 2014 Mar 27.

PMID:
24680372
7.

Suvorexant: first global approval.

Yang LP.

Drugs. 2014 Oct;74(15):1817-22. doi: 10.1007/s40265-014-0294-5. Review.

PMID:
25227290
8.

Discovery and development of orexin receptor antagonists as therapeutics for insomnia.

Winrow CJ, Renger JJ.

Br J Pharmacol. 2014 Jan;171(2):283-93. doi: 10.1111/bph.12261. Review.

9.

New class of sleep drugs may offer a safer night's rest.

Willyard C.

Nat Med. 2012 Jul 6;18(7):996. doi: 10.1038/nm0712-996. No abstract available.

PMID:
22772537
10.

A Review of Suvorexant, Doxepin, Ramelteon, and Tasimelteon for the Treatment of Insomnia in Geriatric Patients.

Edmonds C, Swanoski M.

Consult Pharm. 2017 Mar 1;32(3):156-160. doi: 10.4140/TCP.n.2017.156. Review.

PMID:
28270270
11.

Preclinical and clinical results of dual orexin receptor antagonist, suvorexant (BELSOMRA(®)), a novel therapeutic agent for insomnia.

Tanaka Y, Aoki I, Ishine T, Renger JJ, Winrow CJ, Hisada S.

Nihon Yakurigaku Zasshi. 2016 Jul;148(1):46-56. doi: 10.1254/fpj.148.46. Review. Japanese. No abstract available.

PMID:
27430679
13.

Suvorexant: efficacy and safety profile of a dual orexin receptor antagonist in treating insomnia.

Owen RT.

Drugs Today (Barc). 2016 Jan;52(1):29-40. doi: 10.1358/dot.2016.52.1.2439940. Review.

PMID:
26937493
14.

Electroencephalographic power spectral density profile of the orexin receptor antagonist suvorexant in patients with primary insomnia and healthy subjects.

Ma J, Svetnik V, Snyder E, Lines C, Roth T, Herring WJ.

Sleep. 2014 Oct 1;37(10):1609-19. doi: 10.5665/sleep.4068.

15.

A new class of sedative/hypnotics: dual orexin receptor antagonists.

Simonson W.

Geriatr Nurs. 2014 Nov-Dec;35(6):462-3. doi: 10.1016/j.gerinurse.2014.10.002. Epub 2014 Oct 25. No abstract available.

PMID:
25457290
16.

Orexin receptor antagonists: a new treatment for insomnia?

Riemann D, Spiegelhalder K.

Lancet Neurol. 2014 May;13(5):441-3. doi: 10.1016/S1474-4422(13)70311-9. Epub 2014 Mar 27. No abstract available.

PMID:
24680373
17.

Effect of a new thienodiazepine (We-941) on sleep patterns of normal and insomniac subjects.

Velasco M, Velasco F, Cepeda C, Romo R, Pérez-Toledo MA.

Neuropharmacology. 1981 May;20(5):461-8. No abstract available.

PMID:
7017450
18.

Orexin receptor antagonists.

Christopher JA.

Pharm Pat Anal. 2012 Jul;1(3):329-46. doi: 10.4155/ppa.12.27. Review.

PMID:
24236845
19.

On-the-road driving performance the morning after bedtime use of suvorexant 15 and 30 mg in healthy elderly.

Vermeeren A, Vets E, Vuurman EF, Van Oers AC, Jongen S, Laethem T, Heirman I, Bautmans A, Palcza J, Li X, Troyer MD, Wrishko R, McCrea J, Sun H.

Psychopharmacology (Berl). 2016 Sep;233(18):3341-51. doi: 10.1007/s00213-016-4375-x. Epub 2016 Jul 16.

20.

Preclinical assessment of the abuse potential of the orexin receptor antagonist, suvorexant.

Born S, Gauvin DV, Mukherjee S, Briscoe R.

Regul Toxicol Pharmacol. 2017 Jun;86:181-192. doi: 10.1016/j.yrtph.2017.03.006. Epub 2017 Mar 6.

PMID:
28279667

Supplemental Content

Support Center